Scholarlink

Background <p>Granulomatous mastitis (GM) is a rare inflammatory breast disease primarily affecting reproductive-aged women with a history of breastfeeding. Within GM lesions, <i>Corynebacterium kroppenstedtii</i> has frequently been isolated, suggesting it may play a significant role in the development of GM. It is important to develop the novel therapeutic regimen to fight against the <i>Corynebacterium kroppenstedtii</i> infection.</p> Results <p>In our study, the combination of vancomycin and the lipid-lowering drug Tetrahydrolipstatin (THL) exhibited a synergistic effect against bacteria. Proteomic analysis revealed that potential targets of THL are involved in intermediary metabolism, cellular respiration, lipid metabolism, signaling pathways, virulence, and detoxification and adaptation processes.</p> Conclusions <p>The combination of THL and vancomycin could be a novel therapeutic regimen to enhance clinical outcomes and reduce the recurrence of GM.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Effects of lipid-lowering drug on vancomycin-sensitive Corynebacterium kroppenstedtii

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年3月2日

查看全文
  • Dong Yang,
  • Yanfang Zhang,
  • Ibrahima Sory Sow,
  • Shupeng Zhao,
  • Huifang Xing,
  • Hongping Liang,
  • Chonghua Hao,
  • Rongshan Li,
  • Yanjun Zhang

摘要

Background

Granulomatous mastitis (GM) is a rare inflammatory breast disease primarily affecting reproductive-aged women with a history of breastfeeding. Within GM lesions, Corynebacterium kroppenstedtii has frequently been isolated, suggesting it may play a significant role in the development of GM. It is important to develop the novel therapeutic regimen to fight against the Corynebacterium kroppenstedtii infection.

Results

In our study, the combination of vancomycin and the lipid-lowering drug Tetrahydrolipstatin (THL) exhibited a synergistic effect against bacteria. Proteomic analysis revealed that potential targets of THL are involved in intermediary metabolism, cellular respiration, lipid metabolism, signaling pathways, virulence, and detoxification and adaptation processes.

Conclusions

The combination of THL and vancomycin could be a novel therapeutic regimen to enhance clinical outcomes and reduce the recurrence of GM.